AdaptHealth (AHCO) Q2 2026 earnings review
Profitless Prosperity: Record Volume Erased by Margin Collapse
AdaptHealth delivered accelerating organic revenue growth of 15.9%, propelled by its massive new West Coast capitated contract. However, the cost of this growth has been devastating. Adjusted EBITDA margins reversed, and the company slashed its FY26 EBITDA guidance by nearly 30%. Management cited deep complexities with the capitated contract, a surprise $30M manufacturer price hike, and $60M in stranded overhead following the $235M sale of its Diabetes unit. The strategic pivot to streamline the portfolio makes long-term sense, but near-term execution is severely broken.
🐂 Bull Case
Organic growth accelerated to an impressive 15.9%. The massive West Coast capitated contract is fully scaled, proving AdaptHealth can win and onboard industry-defining partnerships.
The $235M sale of the Diabetes business removes a chronic laggard. Combined with a new sleep eCommerce joint venture, the company is successfully narrowing its focus to its core Sleep and Respiratory strengths.
🐻 Bear Case
The West Coast contract was pitched as a margin-accretive victory, but 'transition complexity' is now expected to cost the company $55M in FY26. Management misjudged the execution costs.
Selling Diabetes leaves $60M of unallocated corporate overhead temporarily stranded on the books. Simultaneously, an unexpected $30M manufacturer price increase demonstrates AdaptHealth's lack of pricing power against suppliers.
⚖️ Verdict: 🔴
Bearish. While top-line acceleration and the divestiture of the Diabetes business are structurally positive, a $200M implied reduction in the FY26 EBITDA midpoint destroys the near-term investment case. Growth that obliterates margins is not rewarded.
Key Themes
FY26 EBITDA Guidance Slashed
Management decimated their FY26 Adjusted EBITDA outlook, dropping the midpoint from $705M down to $505M. The $200M bridge is alarming: -$100M from the Diabetes unit sale (which includes $60M of stranded overhead), -$55M from West Coast capitated contract margin compression, -$30M from a supplier price hike, and -$15M from other portfolio actions. This represents a severe breakdown in operational forecasting.
Capitated Volume Ramps Aggressively
Accelerating. The organic growth engine is roaring at 15.9%, up dramatically from 9.1% in Q1. The West Coast capitated contract is now fully at run-rate, and the company just successfully transitioned another 478,000 members under a new Humana OneHome agreement in Florida and Texas. If they can fix the margins, the volume capture is undeniable.
Supplier Pricing Power
An 'unexpected price increase from one of our manufacturers' triggered a $30M downgrade to the full-year EBITDA forecast. This highlights a critical vulnerability: despite its massive scale, AdaptHealth remains a price-taker from dominant equipment manufacturers (like ResMed or Philips), unable to pass those costs immediately through to fixed capitated payor contracts.
Stranded Overhead from Diabetes Divestiture
While selling the Diabetes unit for $235M simplifies the business, it leaves behind a massive $60M in previously allocated corporate overhead. Management expects roughly half of this to be eliminated within 12 months, meaning AdaptHealth will carry $30M+ in dead-weight expenses into late 2027, pressuring continuing operations margins.
Free Cash Flow Collapse
Reversing. YTD 2026 Free Cash Flow flipped to negative $48.4M, a staggering drop from positive $73.3M in the same period last year. This is driven by the massive upfront CapEx required to stock inventory and secure vehicles/locations for the new capitated contracts. The 'cash-conversion' story of 2025 has entirely evaporated.
Other KPIs
The company took a massive non-cash write-down of goodwill, which drove the GAAP net loss to $145.3M. This indicates that the carrying value of previous acquisitions (likely in Respiratory or Wellness) was severely inflated relative to their current cash-generating power.
Decelerating. Down 3.2% YoY from $136.4M, despite revenue growing 12.7%. The resulting margin compression (down to 17.8% from 20.8% a year ago) illustrates the severe friction costs of onboarding millions of capitated lives.
Management executed a workforce restructuring plan aimed at generating $19 million in annualized savings to combat rapid growth-induced cost pressures. This resulted in $6.1 million of restructuring expenses recorded in the quarter.
Guidance
This reflects the removal of the Diabetes business. Given the Q1 and Q2 revenue run rates, this guidance implies stable, high single-digit to low double-digit ongoing growth for the back half of the year in the core Sleep and Respiratory businesses.
Severely Decelerating. Cut dramatically from the previous $680-$730M range. Even adjusting for the $100M impact of the Diabetes sale, the core business earnings power was cut by $100M due to contract friction, inflation, and portfolio restructuring.
Decelerating. Cut from prior guidance of $175-$225M. This figure crucially includes both continuing and discontinued operations. With H1 FCF sitting at negative $48.4M, the company is entirely reliant on a massive H2 cash flow recovery to hit even this lowered target.
Key Questions
Capitated Contract Economics
You cited a $55 million guidance impact related to the West Coast capitated contract. How much of this is strictly one-time transition friction versus a structural mispricing of the contract's utilization rates and operating costs?
Supplier Inflation Contagion
The $30M unexpected manufacturer price increase is a significant blow. What structural protections do you have in your capitated payor contracts to pass these inflationary equipment costs onto the payors, and are other manufacturers signaling similar hikes?
Stranded Overhead Timeline
You noted $60 million in corporate overhead is now stranded following the Diabetes sale, with half expected to be eliminated within 12 months. Why does it take a full year to cut $30M, and what is the plan for the remaining $30M?
Free Cash Flow Ramp
To hit the midpoint of your revised $100M free cash flow guidance, you need to generate nearly $150M in FCF in the back half of the year. What specific CapEx step-downs or working capital releases give you confidence in that aggressive hockey-stick recovery?